Galera Therapeutics Files Definitive Proxy Statement

TL;DR

Galera Therapeutics (GRTX) proxy filing is out for Oct 17 meeting. Shareholders vote soon.

AI Summary

Galera Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on September 3, 2024, for its annual meeting of stockholders scheduled for October 17, 2024. The filing outlines the information required for the proxy statement, including details about the company's operations and any proposals to be voted on by shareholders.

Why It Matters

This filing is crucial for shareholders as it details the agenda for the upcoming annual meeting, including any proposals requiring their vote, and provides essential information for informed decision-making.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new material financial or operational information that would inherently increase risk.

Key Players & Entities

• Galera Therapeutics, Inc. (company) — Registrant
• October 17, 2024 (date) — Annual Meeting Date
• September 3, 2024 (date) — Filing Date

FAQ

Key Financial Figures

• $0.001 — f record of our common stock, par value $0.001 per share, as of the close of business

Filing Documents

• d817523ddef14a.htm (DEF 14A) — 331KB
• g817523g01g01.jpg (GRAPHIC) — 37KB
• g817523g03l16.jpg (GRAPHIC) — 26KB
• g817523g05a44.jpg (GRAPHIC) — 36KB
• g817523g61e00.jpg (GRAPHIC) — 212KB
• g817523g62o01.jpg (GRAPHIC) — 198KB
• 0001193125-24-211527.txt ( ) — 1024KB

RISK FACTORS

RISK FACTORS 4 QUESTIONS AND ANSWERS REGARDING THIS SOLICITATION AND VOTING AT THE SPECIAL MEETING 8 PROPOSAL 1: APPROVAL OF THE DISSOLUTION PURSUANT TO THE PLAN OF DISSOLUTION 16 CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PROPOSED DISSOLUTION 27 PROPOSAL 2: APPROVAL OF ADJOURNMENT OF SPECIAL MEETING TO SOLICIT ADDITIONAL PROXIES 33

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 34 WHERE YOU CAN FIND ADDITIONAL INFORMATION 36 HOUSEHOLDING 37 STOCKHOLDERS PROPOSALS 38 OTHER MATTERS 39 EXHIBIT A A-1 ANNEX A A-1 Table of Contents PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON OCTOBER 17, 2024 This proxy statement (including the documents incorporated by reference and all appendices attached hereto, the Proxy Statement) is furnished in connection with the solicitation of proxies by the Board of Directors (the Board) of Galera Therapeutics, Inc. (Galera, the Company, we, us, and our) for use at a special meeting of stockholders (including any adjournments, postponements or continuations thereof, the Special Meeting). IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE SPECIAL MEETING TO BE HELD ON OCTOBER 17, 2024: THIS PROXY STATEMENT IS FIRST BEING MADE AVAILABLE OR DISTRIBUTED, AS THE CASE MAY BE, TO STOCKHOLDERS OF RECORD ON SEPTEMBER 3, 2024. PROXY STATEMENT SUMMARY This summary is included to provide an introduction and overview of the information contained in this Proxy Statement. This is a summary only and does not contain all of the information we have included in this Proxy Statement. You should refer to the full Proxy Statement for more information about us and the proposals you are being asked to consider. For more complete information regarding our performance, please review our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (the SEC) on March 28, 2024 and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2024 and June 30, 2024 filed with the SEC on May 13, 2024 and August 14, 2024. INFORMATION ABOUT THE SPECIAL MEETING Time and Date October 17, 2024 at 9:00 a.m. Eastern Time Place The Special Meeting will be held in a virtual format only at www.virtualshareholdermeeting.com/GRTX2024SM. I

RISK FACTORS

RISK FACTORS The following risk factors, together with the other information in this Proxy Statement and in the Risk Factors sections included in the documents incorporated by reference into this Proxy Statement (see the section entitled Where You Can Find Additional Information beginning on page 36 of this Proxy Statement), should be carefully considered before deciding whether to vote to approve the Dissolution Proposal as described in this Proxy Statement. In addition, stockholders should keep in mind that the risks described below are not the only risks that are relevant to your voting decision. The risks described below are the risks regarding the Dissolution that we currently believe are the material risks of which our stockholders should be aware. Nonetheless, additional risks that are not presently known to us, or that we currently believe are not material, may also prove to be important. RISKS RELATED TO THE DISSOLUTION We cannot predict the timing of the distributions to stockholders. Our current intention is that, if approved by our stockholders, the Certificate of Dissolution would be filed promptly after such approval; however, the timing of such filing and the decision of whether or not to proceed with the Dissolution will be made by the Board in its sole discretion and in its own timing. No further stockholder approval would be required to effect the Dissolution. However, if the Board determines that the Dissolution is not in our best interest or the best interest of our stockholders, the Board may, in its sole discretion, abandon the Dissolution or may amend or modify the Plan of Dissolution to the extent permitted by Delaware law without the necessity of further stockholder approval. After the Certificate of Dissolution has been filed, revocation of the Dissolution would require stockholder approval under Delaware law. Under Delaware law, before a dissolved corporation may make any distribution to its stockholders, it must pay or make reas

View Full Filing

View this DEF 14A filing on SEC EDGAR